{"gene":"ZBTB18","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":1997,"finding":"ZBTB18 (C2H2-171) encodes a protein with an N-terminal POZ/BTB domain and four C-terminal C2H2 zinc finger domains, is preferentially expressed in brain neurons (highest in cerebellum), and maps to human chromosome 1q44-ter.","method":"cDNA cloning, sequence analysis, Northern blotting, in situ hybridization","journal":"International journal of developmental neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct molecular characterization of the protein structure and expression by cDNA cloning and Northern blot in a single foundational study","pmids":["9568537"],"is_preprint":false},{"year":2010,"finding":"ZNF238/ZBTB18 is highly expressed in postmitotic cerebellar granule neurons and differentiated neurons; knockdown in mouse granule neuron precursors (GNPs) decreases MAP2, NeuN, and p27 expression, while re-introduction in medulloblastoma and glioblastoma cells decreases cyclin D1, increases MAP2 and p27, reduces proliferation, and promotes cell death, demonstrating an antiproliferative/pro-differentiation function in neural cells.","method":"shRNA knockdown in primary GNPs, overexpression in MB/GBM cell lines, Western blotting, in vivo xenograft tumor suppression assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function with specific molecular readouts, single lab with multiple cell-based and in vivo assays","pmids":["20103640"],"is_preprint":false},{"year":2011,"finding":"RP58/ZBTB18 acts as a transcriptional repressor of proneurogenic genes pax6, ngn2, and neuroD1 (ngn2 and neuroD1 being direct targets), and its CNS-specific conditional knockout causes microencephaly, corpus callosum agenesis, cerebellar hypoplasia, reduced neuronal differentiation, and increased glial differentiation, demonstrating a required role in neuronal differentiation and brain expansion.","method":"Conditional knockout mouse (CNS-specific), chromatin immunoprecipitation (direct target validation), reporter assays, immunohistochemistry","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct target identification by ChIP combined with conditional KO producing specific cellular phenotypes; multiple orthogonal methods in one study","pmids":["22095278"],"is_preprint":false},{"year":2017,"finding":"ZBTB18 is silenced in the mesenchymal subtype of glioblastoma through aberrant promoter methylation; loss of ZBTB18 contributes to aggressive GBM phenotype, and restitution of ZBTB18 expression reverses this phenotype and impairs tumor-forming ability, establishing ZBTB18 as a tumor suppressor regulated epigenetically.","method":"Promoter methylation analysis, ZBTB18 re-expression in GBM cells, gene expression profiling, functional assays (proliferation, invasion)","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with phenotypic readout and epigenetic mechanism identified, single lab with multiple methods","pmids":["28512252"],"is_preprint":false},{"year":2019,"finding":"Disease-associated missense mutations in ZBTB18 (N461S, R495G, and others) that map to DNA-contact residues within the zinc-finger domain alter DNA-binding specificity and transcriptional regulatory activity in vitro, and impair radial migration of newborn neurons in vivo, linking specific zinc-finger residues to DNA contact and neuronal migration.","method":"In silico structural modeling, luciferase reporter transcriptional assays, EMSA/DNA binding assays, in utero electroporation for neuronal migration in vivo","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (structural modeling, in vitro DNA binding, transcriptional assay, in vivo migration) establishing mechanistic link between specific residues and function","pmids":["31112317"],"is_preprint":false},{"year":2020,"finding":"General population ZBTB18 missense variants within the zinc-finger domain alter DNA-binding specificity and transcriptional activity; variants mapping to DNA-contact residues more frequently impair function, whereas variants at non-contact residues are more likely to have negligible functional impact.","method":"EMSA/DNA binding assays, luciferase reporter transcriptional assays, structural analysis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro DNA binding and transcriptional assays on multiple variants, single lab","pmids":["32598555"],"is_preprint":false},{"year":2020,"finding":"CtBP2 physically interacts with ZBTB18 in GBM cells (U-87 MG), and this interaction influences cell proliferation, apoptosis, EMT, and SHH-GLI1 pathway activity in GBM.","method":"Co-immunoprecipitation, immunofluorescence colocalization, shRNA knockdown, xenograft tumor model","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP interaction established, functional consequences shown in multiple assays, single lab","pmids":["32971103"],"is_preprint":false},{"year":2021,"finding":"ZBTB18 directly binds enhancer/promoter regions of genes encoding class I PI3K regulatory subunits (reducing their expression), dampens PI3K signaling, and suppresses plasma cell differentiation in B cells; disease-associated ZBTB18 mutants lose this suppressor activity.","method":"ChIP-seq, reporter assays, B cell functional differentiation assays, loss-of-function mouse model, human B cell validation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct chromatin binding by ChIP-seq, functional differentiation assays in mouse and human B cells, multiple orthogonal methods including mutant analysis","pmids":["33608456"],"is_preprint":false},{"year":2022,"finding":"ZBTB18 interacts with co-activator/co-repressor CTBP1/2 and LSD1 at SREBP gene promoters; ZBTB18 binding is associated with reduced LSD1 demethylase activity (H3K4me2 and H3K9me2) and promotes LSD1 scaffolding with ZNF217, thereby inhibiting SREBP-dependent lipid synthesis in glioblastoma.","method":"Co-immunoprecipitation, ChIP, metabolic assays, glucose tracing/mass spectrometry, gene expression analysis","journal":"Life science alliance","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ChIP showing ZBTB18 binding at SREBP promoters with histone mark analysis, metabolic tracing, and protein interaction studies using multiple orthogonal methods","pmids":["36414381"],"is_preprint":false},{"year":2022,"finding":"In glioblastoma, calpain protease cleaves ZBTB18, generating an N-terminal fragment that localizes to the cytoplasm (unable to repress transcription); this cytoplasmic N-terminal fragment interacts with CTBP1/2 and activates HIF1A-regulated genes, leading to increased lipid uptake, lipid droplet accumulation, and enhanced metabolic activity.","method":"Mass spectrometry, subcellular fractionation, co-immunoprecipitation, calpain inhibitor treatment, gene expression analysis, lipid assays","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-based identification of cleavage fragment and interactors, functional assays for HIF1A target activation, single lab with multiple methods","pmids":["35800763"],"is_preprint":false},{"year":2023,"finding":"ZBTB18 acts as a transcriptional repressor that reduces chromatin accessibility at promoters of metastasis-driving genes (e.g., Tgfbr2), preventing TGFβ1 pathway activation, reducing cell migration and invasion, and inducing widespread chromatin closing; loss of ZBTB18 activity defines metastasis-competent cancer cells.","method":"ATAC-seq (chromatin accessibility), RNA-seq, cell migration/invasion assays, mouse metastasis models, ZBTB18 re-expression","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ATAC-seq genome-wide chromatin accessibility combined with in vivo metastasis models and specific pathway (TGFβ) validation using multiple orthogonal methods","pmids":["36608120"],"is_preprint":false},{"year":2023,"finding":"ZBTB18/RP58 haploinsufficiency in heterozygous knockout mice causes glutamatergic synaptic dysfunction, including reduced glutamate receptor expression, altered NMDA receptor-mediated synaptic responses, decreased LTP saturation, and altered thick-spine morphology, alongside corpus callosum dysplasia and behavioral/cognitive deficits.","method":"Heterozygous knockout mouse, electrophysiology (LTP, NMDA currents), Western blotting, spine morphology analysis, behavioral testing","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined cellular and synaptic phenotypes with multiple electrophysiological and molecular readouts in a loss-of-function mouse model, single lab","pmids":["36721027"],"is_preprint":false},{"year":2024,"finding":"Hepatic ZBTB18 transcriptionally activates FXR (Farnesoid X receptor) to promote fatty acid oxidation and transcriptionally activates Clathrin Heavy Chain (CLTC) to inhibit NLRP3 inflammasome activity; hepatic ZBTB18 knockout promotes NAFLD features and insulin resistance, while overexpression alleviates hepatosteatosis.","method":"Hepatic-specific knockout and overexpression in mice, primary hepatocyte cultures, FXR deletion and forced expression, CLTC deletion, in vitro and in vivo mechanistic assays","journal":"Signal transduction and targeted therapy","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic epistasis via FXR and CLTC deletion to verify downstream mechanism, multiple in vivo and in vitro models with specific readouts","pmids":["38263084"],"is_preprint":false},{"year":2024,"finding":"ZBTB18 physically interacts with p21 to co-repress expression of cKit in hematopoietic stem cells (HSCs), regulating HSC self-renewal; Zbtb18 knockdown significantly impairs HSC reconstitution capability.","method":"Co-immunoprecipitation, p21-tdTomato reporter mouse, shRNA knockdown, HSC transplantation/reconstitution assay","journal":"Protein & cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction by Co-IP, functional HSC reconstitution assay with knockdown, single lab","pmids":["38721703"],"is_preprint":false},{"year":2024,"finding":"ZBTB18 haploinsufficiency in mice leads to defective DNA repair, DNA and mitochondrial damage accumulation, and activated microglia in the dentate gyrus, contributing to early cognitive decline; these phenotypes are attenuated by minocycline treatment.","method":"Zbtb18 heterozygous knockout mice, DNA damage markers, mitochondrial morphology analysis, microglial activation assay, transcriptome analysis, behavioral testing, minocycline intervention","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function mouse with specific molecular (DNA repair, mitochondrial) and cellular (microglial) readouts, single lab with multiple methods","pmids":["39396010"],"is_preprint":false},{"year":2024,"finding":"ZBTB18 regulates cytokine production in glioblastoma cells, impairing secretion of chemoattractants for glioma-associated macrophages/microglia (GAMs); ZBTB18 expression in GBM cells reduces GAM migration and alters microglia commitment from immunosuppressive to pro-inflammatory phenotype in vivo.","method":"ZBTB18 re-expression in GBM cells, conditioned medium assays, in vivo tumor models, RNA-seq of conditioned microglia","journal":"Communications biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ZBTB18 expression-based functional experiments with in vivo validation and RNA-seq mechanistic readout, single lab","pmids":["39516530"],"is_preprint":false},{"year":2025,"finding":"T cell-derived IL-9 induces ZBTB18 expression in germinal center (GC) memory precursor B cells; ZBTB18 is required for GC-derived memory B cell development and directly represses cyclin and CDK genes, pro-apoptotic genes Bid and Casp3, and the GC-retaining receptor S1pr2, enabling memory B cell exit and survival.","method":"Adoptive transfer, radiation chimera models, conditional ZBTB18 knockout in B cells, ChIP, gene expression analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genetic epistasis (conditional KO), direct target identification by ChIP, multiple in vivo models across different cell types, mechanistic pathway (IL-9→ZBTB18→target genes) validated orthogonally","pmids":["40107273"],"is_preprint":false},{"year":2025,"finding":"ZBTB18 binds mammalian-specific cis-regulatory elements (CREs) associated with intratelencephalic (IT) and extratelencephalic (ET) neuron identity genes; deletion of Zbtb18 in mouse excitatory neurons dysregulates target gene expression, reduces neuronal molecular diversity, diminishes corticospinal and callosal projections, and increases intrahemispheric association projections, resembling non-mammalian dorsal pallium organization.","method":"ATAC-seq, RNA-seq, ChIP/CUT&RUN for ZBTB18 binding, conditional Zbtb18 knockout in excitatory neurons, axonal projection tracing, cross-species CRE conservation analysis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with direct genomic binding data and specific axonal projection phenotypes, preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.05.20.652233"],"is_preprint":true},{"year":2023,"finding":"ZBTB18 forms a transcriptional repressive complex with FOXG1 involved in neuronal differentiation; missense variants within the BTB domain (in addition to the zinc finger domain) can be pathogenic, expanding the known domain regions where mutations disrupt ZBTB18 function.","method":"Whole-exome sequencing, clinical genetic analysis; BTB domain variant identified in monozygotic twins","journal":"Cytogenetic and genome research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — complex formation with FOXG1 stated but mechanistic experiment not described in abstract; BTB domain pathogenicity from clinical variant only","pmids":["38056433"],"is_preprint":false},{"year":2026,"finding":"ZBTB18 inhibits muscle stem cell (MuSC) proliferation and promotes myogenic differentiation with a bias toward oxidative myofiber formation by acting as a transcriptional repressor of STAT1.","method":"ATAC-seq, RNA-seq in bovine MuSCs, functional proliferation/differentiation assays, ZBTB18 overexpression/knockdown, ChIP or reporter assay for STAT1 repression","journal":"Food chemistry. Molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — integrated ATAC-seq/RNA-seq plus functional myogenesis assays establishing STAT1 as direct transcriptional target, single lab","pmids":["42256346"],"is_preprint":false}],"current_model":"ZBTB18 is a BTB-POZ domain and multi-C2H2 zinc finger transcriptional repressor that directly binds DNA through its zinc finger domain to repress target genes (including proneurogenic genes Ngn2/NeuroD1/Pax6, PI3K subunits, SREBP genes, cKit, S1pr2, cyclin/CDK genes, and STAT1); it interacts with co-repressor/co-activator complexes including CTBP1/2 and LSD1, is post-translationally cleaved by calpain in glioblastoma generating a cytoplasmic N-terminal fragment that activates HIF1A targets, and is regulated epigenetically by promoter methylation; functionally, it is required for neuronal differentiation, corpus callosum development, excitatory synapse maturation, memory B cell development downstream of IL-9, suppression of tumor metastasis via chromatin compaction, fatty acid oxidation via FXR activation in hepatocytes, and hematopoietic stem cell self-renewal in complex with p21."},"narrative":{"mechanistic_narrative":"ZBTB18 (RP58/ZNF238) is a BTB-POZ/C2H2 zinc-finger transcriptional repressor that controls cell-fate decisions across neural, immune, hematopoietic, hepatic, and muscle lineages by binding DNA through its zinc-finger domain to silence lineage- and proliferation-controlling gene programs [PMID:9568537, PMID:22095278, PMID:31112317]. In the developing brain it directly represses the proneurogenic genes Ngn2 and NeuroD1 (and regulates Pax6), and its loss causes microencephaly, corpus callosum agenesis, cerebellar hypoplasia, and a shift from neuronal toward glial differentiation [PMID:22095278]; it acts as an antiproliferative, pro-differentiation factor that lowers cyclin D1 and raises p27 and neuronal markers [PMID:20103640]. Disease-associated missense variants clustered at DNA-contact residues of the zinc fingers alter DNA-binding specificity and transcriptional activity and impair neuronal radial migration, mechanistically tying specific residues to ZBTB18 function [PMID:31112317, PMID:32598555]. Repression is achieved through chromatin-modifying partners: ZBTB18 binds CTBP1/2 and LSD1 to scaffold repressive complexes and reduce LSD1 demethylase activity at target promoters, and genome-wide it reduces chromatin accessibility, compacting promoters of metastasis-driving genes such as Tgfbr2 to block TGFβ pathway activation and invasion [PMID:36414381, PMID:36608120]. Across other tissues ZBTB18 directly represses class I PI3K regulatory subunits to dampen PI3K signaling and restrain plasma cell differentiation [PMID:33608456], co-represses cKit with p21 to govern hematopoietic stem cell self-renewal [PMID:38721703], and is induced by IL-9 to drive memory B cell development by repressing cyclin/CDK, pro-apoptotic (Bid, Casp3), and the retention receptor S1pr2 genes [PMID:40107273]. In glioblastoma ZBTB18 is silenced by promoter methylation and functions as a tumor suppressor whose re-expression reverses the aggressive phenotype [PMID:28512252]; calpain cleavage generates a cytoplasmic N-terminal fragment that loses repressor activity and instead, via CTBP1/2, activates HIF1A target genes to promote lipid uptake and metabolic reprogramming [PMID:35800763]. In hepatocytes ZBTB18 transcriptionally activates FXR and CLTC to promote fatty acid oxidation and limit NLRP3 inflammasome activity, protecting against NAFLD [PMID:38263084].","teleology":[{"year":1997,"claim":"Establishing ZBTB18 as a neuron-enriched protein with a defined BTB/zinc-finger architecture set the structural basis for its candidacy as a sequence-specific transcriptional regulator.","evidence":"cDNA cloning, sequence analysis, and Northern/in situ expression mapping in brain","pmids":["9568537"],"confidence":"Medium","gaps":["No DNA target or transcriptional activity demonstrated","Functional role inferred only from expression pattern"]},{"year":2010,"claim":"Loss- and gain-of-function in neural cells answered whether ZBTB18 controls proliferation versus differentiation, defining it as an antiproliferative, pro-differentiation factor.","evidence":"shRNA knockdown in primary granule neuron precursors and overexpression in medulloblastoma/glioblastoma lines with marker readouts and xenograft assay","pmids":["20103640"],"confidence":"Medium","gaps":["Direct transcriptional targets not identified","Mechanism of cyclin D1/p27 regulation not resolved"]},{"year":2011,"claim":"ChIP plus conditional knockout identified Ngn2 and NeuroD1 as direct repression targets and established ZBTB18 as required for neuronal differentiation and brain expansion.","evidence":"CNS-specific conditional knockout mouse, ChIP target validation, reporter assays, immunohistochemistry","pmids":["22095278"],"confidence":"High","gaps":["Co-repressor machinery at these promoters not defined","Whether Pax6 is a direct vs indirect target unresolved"]},{"year":2019,"claim":"Mapping disease variants to zinc-finger DNA-contact residues mechanistically connected specific amino acids to DNA binding, transcriptional output, and in vivo neuronal migration.","evidence":"Structural modeling, EMSA/DNA binding, luciferase reporters, in utero electroporation migration assays","pmids":["31112317"],"confidence":"High","gaps":["Genome-wide target consequences of variants not assessed","Effect on co-repressor recruitment not tested"]},{"year":2020,"claim":"Extending variant analysis to population variants clarified that DNA-contact residue mutations preferentially impair function while non-contact variants are often tolerated, refining genotype-function rules.","evidence":"EMSA/DNA binding and reporter transcriptional assays on multiple variants with structural analysis","pmids":["32598555"],"confidence":"Medium","gaps":["In vivo phenotypic correlation for population variants lacking","Single-lab in vitro assays only"]},{"year":2020,"claim":"Identifying CtBP2 as a physical partner in glioblastoma began defining the co-repressor complexes through which ZBTB18 acts.","evidence":"Co-immunoprecipitation, colocalization, shRNA knockdown, xenograft model in U-87 MG cells","pmids":["32971103"],"confidence":"Medium","gaps":["Direct vs bridged interaction not distinguished","Target genes of the ZBTB18-CtBP2 complex not mapped"]},{"year":2021,"claim":"ChIP-seq in B cells answered how ZBTB18 restrains differentiation, showing it directly represses class I PI3K regulatory subunits to dampen PI3K signaling and block plasma cell differentiation.","evidence":"ChIP-seq, reporter assays, loss-of-function mouse and human B cell differentiation assays, mutant analysis","pmids":["33608456"],"confidence":"High","gaps":["Co-repressor requirement at PI3K loci not defined","Upstream signals controlling ZBTB18 levels in B cells unaddressed"]},{"year":2022,"claim":"Defining ZBTB18-CTBP1/2-LSD1 complexes at SREBP promoters established a chromatin-modifying mechanism linking ZBTB18 to lipid metabolism in glioblastoma.","evidence":"Co-IP, ChIP with histone mark analysis, glucose tracing/mass spectrometry, metabolic assays","pmids":["36414381"],"confidence":"High","gaps":["Direct vs scaffolding contribution of ZBTB18 to LSD1 activity not fully separated","Generality beyond SREBP loci unknown"]},{"year":2022,"claim":"Discovery of calpain cleavage explained how a repressor can be converted to a metabolic activator, generating a cytoplasmic N-terminal fragment that engages CTBP1/2 and activates HIF1A targets.","evidence":"Mass spectrometry, subcellular fractionation, Co-IP, calpain inhibition, lipid assays","pmids":["35800763"],"confidence":"Medium","gaps":["Cleavage site and regulation of calpain activation not fully mapped","Mechanism of cytoplasmic HIF1A target activation unresolved"]},{"year":2023,"claim":"Genome-wide chromatin accessibility profiling showed ZBTB18 enforces widespread chromatin closing, repressing Tgfbr2 and blocking TGFβ-driven metastasis, defining loss of ZBTB18 as a metastasis-enabling event.","evidence":"ATAC-seq, RNA-seq, migration/invasion assays, mouse metastasis models, re-expression","pmids":["36608120"],"confidence":"High","gaps":["How ZBTB18 directs broad chromatin compaction mechanistically not resolved","Partner requirements for accessibility changes not defined"]},{"year":2023,"claim":"Haploinsufficient mice revealed a postnatal role in glutamatergic synapse maturation and cognition beyond developmental patterning.","evidence":"Heterozygous knockout mice, LTP and NMDA electrophysiology, Western blot, spine morphology, behavior","pmids":["36721027"],"confidence":"Medium","gaps":["Direct synaptic gene targets not identified","Cell-autonomy of synaptic deficits not established"]},{"year":2023,"claim":"Clinical genetics extended pathogenic variation into the BTB domain and reported a FOXG1-containing repressive complex, broadening the functional domains and partner set.","evidence":"Whole-exome sequencing and clinical analysis in monozygotic twins","pmids":["38056433"],"confidence":"Low","gaps":["FOXG1 complex formation asserted but not mechanistically demonstrated","BTB-domain variant pathogenicity from clinical association only"]},{"year":2024,"claim":"Hepatic genetic models defined a metabolic-protective program in which ZBTB18 activates FXR and CLTC to drive fatty acid oxidation and limit NLRP3 inflammasome activity.","evidence":"Hepatic-specific knockout/overexpression mice, primary hepatocytes, FXR and CLTC deletion epistasis","pmids":["38263084"],"confidence":"High","gaps":["Whether FXR/CLTC are direct ZBTB18 targets via repression or activation mechanistically reconciled with its repressor role unclear","Tissue-specificity of activating function not explained"]},{"year":2024,"claim":"Identifying a ZBTB18-p21 complex repressing cKit established its role in hematopoietic stem cell self-renewal.","evidence":"Co-IP, p21-tdTomato reporter mouse, shRNA knockdown, HSC transplantation/reconstitution","pmids":["38721703"],"confidence":"Medium","gaps":["Direct cKit promoter binding by ZBTB18 not shown","Single-lab interaction data"]},{"year":2024,"claim":"Haploinsufficient mice linked ZBTB18 loss to defective DNA repair, mitochondrial damage, and microglial activation driving cognitive decline, reversible by minocycline.","evidence":"Heterozygous knockout mice, DNA damage and mitochondrial markers, microglial assays, transcriptome, behavior, drug intervention","pmids":["39396010"],"confidence":"Medium","gaps":["Direct transcriptional control of DNA-repair genes not demonstrated","Whether microglial phenotype is cell-autonomous vs secondary unclear"]},{"year":2024,"claim":"ZBTB18 re-expression in glioblastoma was shown to reshape the tumor microenvironment by reducing chemoattractant secretion and shifting microglia toward a pro-inflammatory state.","evidence":"Re-expression in GBM cells, conditioned medium assays, in vivo tumor models, RNA-seq of conditioned microglia","pmids":["39516530"],"confidence":"Medium","gaps":["Direct cytokine gene targets of ZBTB18 not defined","Mechanism linking transcriptional repression to secretome change unresolved"]},{"year":2025,"claim":"IL-9 induction of ZBTB18 and ChIP target mapping established a cytokine-driven program enabling germinal center memory B cell exit and survival via repression of cyclin/CDK, pro-apoptotic, and S1pr2 genes.","evidence":"Adoptive transfer, radiation chimeras, conditional B cell knockout, ChIP, expression analysis","pmids":["40107273"],"confidence":"High","gaps":["How IL-9 signaling induces ZBTB18 transcription not detailed","Co-repressor machinery at these B cell loci not characterized"]},{"year":2025,"claim":"Integrating ZBTB18 binding at mammalian-specific cis-regulatory elements with conditional knockout connected ZBTB18 to evolutionarily novel cortical neuron diversity and projection identity.","evidence":"ATAC-seq, RNA-seq, ChIP/CUT&RUN, conditional knockout in excitatory neurons, axonal tracing, cross-species CRE analysis (preprint)","pmids":["bio_10.1101_2025.05.20.652233"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Direct vs indirect control of IT/ET identity genes not fully separated"]},{"year":2026,"claim":"ATAC-seq/RNA-seq plus functional myogenesis assays extended ZBTB18's repressor role to muscle stem cells, showing repression of STAT1 promotes oxidative myofiber differentiation.","evidence":"ATAC-seq, RNA-seq in bovine MuSCs, proliferation/differentiation assays, ZBTB18 perturbation, STAT1 repression validation","pmids":["42256346"],"confidence":"Medium","gaps":["Conservation of STAT1 repression in human/mouse muscle untested","Co-repressor dependence at STAT1 locus not addressed"]},{"year":null,"claim":"How ZBTB18 selects its tissue-specific target repertoire and switches between repressive (full-length, chromatin-compacting) and activating (cleaved/cytoplasmic; hepatic FXR/CLTC) outputs remains the central unresolved mechanistic question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model reconciling repressor activity with reported transcriptional activation of FXR/CLTC","Structural basis for partner choice (CTBP1/2, LSD1, FOXG1, p21) across tissues unknown","Determinants of context-specific cis-element binding not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,7,8,10,16,19]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,5,7]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,8]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,7,8,16,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,11,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,10]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,9,12]}],"complexes":[],"partners":["CTBP1","CTBP2","LSD1","ZNF217","FOXG1","CDKN1A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99592","full_name":"Zinc finger and BTB domain-containing protein 18","aliases":["58 kDa repressor protein","Transcriptional repressor RP58","Translin-associated zinc finger protein 1","TAZ-1","Zinc finger protein 238","Zinc finger protein C2H2-171"],"length_aa":522,"mass_kda":58.4,"function":"Transcriptional repressor that plays a role in various developmental processes such as myogenesis and brain development. Plays a key role in myogenesis by directly repressing the expression of ID2 and ID3, 2 inhibitors of skeletal myogenesis. Also involved in controlling cell division of progenitor cells and regulating the survival of postmitotic cortical neurons. Specifically binds the consensus DNA sequence 5'-[AC]ACATCTG[GT][AC]-3' which contains the E box core, and acts by recruiting chromatin remodeling multiprotein complexes. May also play a role in the organization of chromosomes in the nucleus","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q99592/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZBTB18","classification":"Not Classified","n_dependent_lines":24,"n_total_lines":1208,"dependency_fraction":0.019867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ZBTB18","total_profiled":1310},"omim":[{"mim_id":"612337","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 22; MRD22","url":"https://www.omim.org/entry/612337"},{"mim_id":"608433","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 18; ZBTB18","url":"https://www.omim.org/entry/608433"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear speckles","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":265.0}],"url":"https://www.proteinatlas.org/search/ZBTB18"},"hgnc":{"alias_symbol":["C2H2-171","TAZ-1","RP58"],"prev_symbol":["ZNF238"]},"alphafold":{"accession":"Q99592","domains":[{"cath_id":"3.30.160","chopping":"466-494","consensus_level":"medium","plddt":80.0476,"start":466,"end":494}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99592","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99592-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99592-F1-predicted_aligned_error_v6.png","plddt_mean":51.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZBTB18","jax_strain_url":"https://www.jax.org/strain/search?query=ZBTB18"},"sequence":{"accession":"Q99592","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99592.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99592/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99592"}},"corpus_meta":[{"pmid":"28283832","id":"PMC_28283832","title":"Genetic and phenotypic dissection of 1q43q44 microdeletion syndrome and neurodevelopmental phenotypes associated with mutations in ZBTB18 and HNRNPU.","date":"2017","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28283832","citation_count":68,"is_preprint":false},{"pmid":"22095278","id":"PMC_22095278","title":"RP58/ZNF238 directly modulates proneurogenic gene levels and is required for neuronal differentiation and brain expansion.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22095278","citation_count":66,"is_preprint":false},{"pmid":"20103640","id":"PMC_20103640","title":"ZNF238 is expressed in postmitotic brain cells and inhibits brain tumor growth.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20103640","citation_count":43,"is_preprint":false},{"pmid":"24193349","id":"PMC_24193349","title":"A de novo non-sense mutation in ZBTB18 in a patient with features of the 1q43q44 microdeletion syndrome.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/24193349","citation_count":43,"is_preprint":false},{"pmid":"28512252","id":"PMC_28512252","title":"Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28512252","citation_count":34,"is_preprint":false},{"pmid":"26107416","id":"PMC_26107416","title":"Differential expression of id genes and their potential regulator znf238 in zebrafish adult neural progenitor cells and neurons suggests distinct functions in adult neurogenesis.","date":"2015","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/26107416","citation_count":30,"is_preprint":false},{"pmid":"27598823","id":"PMC_27598823","title":"Further evidence that de novo missense and truncating variants in ZBTB18 cause intellectual disability with variable features.","date":"2016","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27598823","citation_count":29,"is_preprint":false},{"pmid":"23494996","id":"PMC_23494996","title":"Haploinsufficiency of ZNF238 is associated with corpus callosum abnormalities in 1q44 deletions.","date":"2013","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/23494996","citation_count":27,"is_preprint":false},{"pmid":"29573576","id":"PMC_29573576","title":"Toward clinical and molecular understanding of pathogenic variants in the ZBTB18 gene.","date":"2018","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29573576","citation_count":24,"is_preprint":false},{"pmid":"38263084","id":"PMC_38263084","title":"Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor).","date":"2024","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38263084","citation_count":23,"is_preprint":false},{"pmid":"33685441","id":"PMC_33685441","title":"CircTP63 promotes hepatocellular carcinoma progression by sponging miR-155-5p and upregulating ZBTB18.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33685441","citation_count":19,"is_preprint":false},{"pmid":"9568537","id":"PMC_9568537","title":"C2H2-171: a novel human cDNA representing a developmentally regulated POZ domain/zinc finger protein preferentially expressed in brain.","date":"1997","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9568537","citation_count":17,"is_preprint":false},{"pmid":"36608120","id":"PMC_36608120","title":"ZBTB18 restricts chromatin accessibility and prevents transcriptional adaptations that drive metastasis.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36608120","citation_count":15,"is_preprint":false},{"pmid":"31112317","id":"PMC_31112317","title":"Disease-associated missense variants in ZBTB18 disrupt DNA binding and impair the development of neurons within the embryonic cerebral cortex.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31112317","citation_count":15,"is_preprint":false},{"pmid":"36414381","id":"PMC_36414381","title":"ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma.","date":"2022","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/36414381","citation_count":13,"is_preprint":false},{"pmid":"40107273","id":"PMC_40107273","title":"An interleukin-9-ZBTB18 axis promotes germinal center development of memory B cells.","date":"2025","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/40107273","citation_count":12,"is_preprint":false},{"pmid":"35083747","id":"PMC_35083747","title":"Understanding the impact of ZBTB18 missense variation on transcription factor function in neurodevelopment and disease.","date":"2022","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35083747","citation_count":10,"is_preprint":false},{"pmid":"33892786","id":"PMC_33892786","title":"Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis.","date":"2021","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33892786","citation_count":9,"is_preprint":false},{"pmid":"32598555","id":"PMC_32598555","title":"General population ZBTB18 missense variants influence DNA binding and transcriptional regulation.","date":"2020","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/32598555","citation_count":8,"is_preprint":false},{"pmid":"32971103","id":"PMC_32971103","title":"CtBP2 interacts with ZBTB18 to promote malignancy of glioblastoma.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32971103","citation_count":8,"is_preprint":false},{"pmid":"35800763","id":"PMC_35800763","title":"Calpain-mediated cleavage generates a ZBTB18 N-terminal product that regulates HIF1A signaling and glioblastoma metabolism.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35800763","citation_count":8,"is_preprint":false},{"pmid":"39516530","id":"PMC_39516530","title":"ZBTB18 regulates cytokine expression and affects microglia/macrophage recruitment and commitment in glioblastoma.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/39516530","citation_count":6,"is_preprint":false},{"pmid":"28345786","id":"PMC_28345786","title":"A de novo nonsense mutation in ZBTB18 plus a de novo 15q13.3 microdeletion in a 6-year-old female.","date":"2017","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/28345786","citation_count":6,"is_preprint":false},{"pmid":"33608456","id":"PMC_33608456","title":"The Zinc Finger Protein Zbtb18 Represses Expression of Class I Phosphatidylinositol 3-Kinase Subunits and Inhibits Plasma Cell Differentiation.","date":"2021","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/33608456","citation_count":5,"is_preprint":false},{"pmid":"33621064","id":"PMC_33621064","title":"Structure-Based Approaches to Classify the Functional Impact of ZBTB18 Missense Variants in Health and Disease.","date":"2021","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33621064","citation_count":5,"is_preprint":false},{"pmid":"38721703","id":"PMC_38721703","title":"p21/Zbtb18 repress the expression of cKit to regulate the self-renewal of hematopoietic stem cells.","date":"2024","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/38721703","citation_count":4,"is_preprint":false},{"pmid":"36721027","id":"PMC_36721027","title":"The mouse model of intellectual disability by ZBTB18/RP58 haploinsufficiency shows cognitive dysfunction with synaptic impairment.","date":"2023","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/36721027","citation_count":4,"is_preprint":false},{"pmid":"39396010","id":"PMC_39396010","title":"Minocycline prevents early age-related cognitive decline in a mouse model of intellectual disability caused by ZBTB18/RP58 haploinsufficiency.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39396010","citation_count":3,"is_preprint":false},{"pmid":"38056433","id":"PMC_38056433","title":"Expanding the Clinical and Molecular Spectrum of FOXG1- and ZBTB18-Associated Neurodevelopmental Disorders.","date":"2023","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/38056433","citation_count":2,"is_preprint":false},{"pmid":"37525067","id":"PMC_37525067","title":"A novel heterozygous ZBTB18 missense mutation in a family with non-syndromic intellectual disability.","date":"2023","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/37525067","citation_count":1,"is_preprint":false},{"pmid":"38215144","id":"PMC_38215144","title":"A de novo variant in ZBTB18 gene caused autosomal dominant non-syndromic intellectual disability 22 syndrome: A case report and literature review.","date":"2024","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38215144","citation_count":1,"is_preprint":false},{"pmid":"35315038","id":"PMC_35315038","title":"[Analysis of clinical features and ZBTB18 gene variant in a child with autosomal dominant mental disorder type 22].","date":"2022","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35315038","citation_count":1,"is_preprint":false},{"pmid":"34907638","id":"PMC_34907638","title":"Prenatal diagnosis of a likely pathogenic variant in ZBTB18: Natural evolution of fetal phenotype including the long bones and corpus callosum.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34907638","citation_count":1,"is_preprint":false},{"pmid":"40203804","id":"PMC_40203804","title":"IL-9 and ZBTB18 are germinal center memory makers.","date":"2025","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/40203804","citation_count":0,"is_preprint":false},{"pmid":"42183389","id":"PMC_42183389","title":"Identification of De Novo ZBTB18 Variant in a Patient With Global Developmental Delay, Seizures, and Juvenile Facies.","date":"2026","source":"International journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/42183389","citation_count":0,"is_preprint":false},{"pmid":"42256346","id":"PMC_42256346","title":"ZBTB18-mediated STAT1 transcriptional repression contributes to bovine myogenesis, implying an association with oxidative myofiber formation and beef eating quality.","date":"2026","source":"Food chemistry. Molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/42256346","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.20.652233","title":"Adaptive Evolution of Gene Regulatory Networks in Mammalian Neocortical Neurons","date":"2025-05-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.20.652233","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.26.660775","title":"Competing Programs Shape Cortical Sensorimotor-Association Axis Development","date":"2025-06-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.26.660775","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19809,"output_tokens":4957,"usd":0.066891,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13330,"output_tokens":5806,"usd":0.1059,"stage2_stop_reason":"end_turn"},"total_usd":0.172791,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"ZBTB18 (C2H2-171) encodes a protein with an N-terminal POZ/BTB domain and four C-terminal C2H2 zinc finger domains, is preferentially expressed in brain neurons (highest in cerebellum), and maps to human chromosome 1q44-ter.\",\n      \"method\": \"cDNA cloning, sequence analysis, Northern blotting, in situ hybridization\",\n      \"journal\": \"International journal of developmental neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct molecular characterization of the protein structure and expression by cDNA cloning and Northern blot in a single foundational study\",\n      \"pmids\": [\"9568537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZNF238/ZBTB18 is highly expressed in postmitotic cerebellar granule neurons and differentiated neurons; knockdown in mouse granule neuron precursors (GNPs) decreases MAP2, NeuN, and p27 expression, while re-introduction in medulloblastoma and glioblastoma cells decreases cyclin D1, increases MAP2 and p27, reduces proliferation, and promotes cell death, demonstrating an antiproliferative/pro-differentiation function in neural cells.\",\n      \"method\": \"shRNA knockdown in primary GNPs, overexpression in MB/GBM cell lines, Western blotting, in vivo xenograft tumor suppression assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function with specific molecular readouts, single lab with multiple cell-based and in vivo assays\",\n      \"pmids\": [\"20103640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RP58/ZBTB18 acts as a transcriptional repressor of proneurogenic genes pax6, ngn2, and neuroD1 (ngn2 and neuroD1 being direct targets), and its CNS-specific conditional knockout causes microencephaly, corpus callosum agenesis, cerebellar hypoplasia, reduced neuronal differentiation, and increased glial differentiation, demonstrating a required role in neuronal differentiation and brain expansion.\",\n      \"method\": \"Conditional knockout mouse (CNS-specific), chromatin immunoprecipitation (direct target validation), reporter assays, immunohistochemistry\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct target identification by ChIP combined with conditional KO producing specific cellular phenotypes; multiple orthogonal methods in one study\",\n      \"pmids\": [\"22095278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZBTB18 is silenced in the mesenchymal subtype of glioblastoma through aberrant promoter methylation; loss of ZBTB18 contributes to aggressive GBM phenotype, and restitution of ZBTB18 expression reverses this phenotype and impairs tumor-forming ability, establishing ZBTB18 as a tumor suppressor regulated epigenetically.\",\n      \"method\": \"Promoter methylation analysis, ZBTB18 re-expression in GBM cells, gene expression profiling, functional assays (proliferation, invasion)\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with phenotypic readout and epigenetic mechanism identified, single lab with multiple methods\",\n      \"pmids\": [\"28512252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Disease-associated missense mutations in ZBTB18 (N461S, R495G, and others) that map to DNA-contact residues within the zinc-finger domain alter DNA-binding specificity and transcriptional regulatory activity in vitro, and impair radial migration of newborn neurons in vivo, linking specific zinc-finger residues to DNA contact and neuronal migration.\",\n      \"method\": \"In silico structural modeling, luciferase reporter transcriptional assays, EMSA/DNA binding assays, in utero electroporation for neuronal migration in vivo\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (structural modeling, in vitro DNA binding, transcriptional assay, in vivo migration) establishing mechanistic link between specific residues and function\",\n      \"pmids\": [\"31112317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"General population ZBTB18 missense variants within the zinc-finger domain alter DNA-binding specificity and transcriptional activity; variants mapping to DNA-contact residues more frequently impair function, whereas variants at non-contact residues are more likely to have negligible functional impact.\",\n      \"method\": \"EMSA/DNA binding assays, luciferase reporter transcriptional assays, structural analysis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro DNA binding and transcriptional assays on multiple variants, single lab\",\n      \"pmids\": [\"32598555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CtBP2 physically interacts with ZBTB18 in GBM cells (U-87 MG), and this interaction influences cell proliferation, apoptosis, EMT, and SHH-GLI1 pathway activity in GBM.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence colocalization, shRNA knockdown, xenograft tumor model\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP interaction established, functional consequences shown in multiple assays, single lab\",\n      \"pmids\": [\"32971103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZBTB18 directly binds enhancer/promoter regions of genes encoding class I PI3K regulatory subunits (reducing their expression), dampens PI3K signaling, and suppresses plasma cell differentiation in B cells; disease-associated ZBTB18 mutants lose this suppressor activity.\",\n      \"method\": \"ChIP-seq, reporter assays, B cell functional differentiation assays, loss-of-function mouse model, human B cell validation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct chromatin binding by ChIP-seq, functional differentiation assays in mouse and human B cells, multiple orthogonal methods including mutant analysis\",\n      \"pmids\": [\"33608456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZBTB18 interacts with co-activator/co-repressor CTBP1/2 and LSD1 at SREBP gene promoters; ZBTB18 binding is associated with reduced LSD1 demethylase activity (H3K4me2 and H3K9me2) and promotes LSD1 scaffolding with ZNF217, thereby inhibiting SREBP-dependent lipid synthesis in glioblastoma.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, metabolic assays, glucose tracing/mass spectrometry, gene expression analysis\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ChIP showing ZBTB18 binding at SREBP promoters with histone mark analysis, metabolic tracing, and protein interaction studies using multiple orthogonal methods\",\n      \"pmids\": [\"36414381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In glioblastoma, calpain protease cleaves ZBTB18, generating an N-terminal fragment that localizes to the cytoplasm (unable to repress transcription); this cytoplasmic N-terminal fragment interacts with CTBP1/2 and activates HIF1A-regulated genes, leading to increased lipid uptake, lipid droplet accumulation, and enhanced metabolic activity.\",\n      \"method\": \"Mass spectrometry, subcellular fractionation, co-immunoprecipitation, calpain inhibitor treatment, gene expression analysis, lipid assays\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-based identification of cleavage fragment and interactors, functional assays for HIF1A target activation, single lab with multiple methods\",\n      \"pmids\": [\"35800763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZBTB18 acts as a transcriptional repressor that reduces chromatin accessibility at promoters of metastasis-driving genes (e.g., Tgfbr2), preventing TGFβ1 pathway activation, reducing cell migration and invasion, and inducing widespread chromatin closing; loss of ZBTB18 activity defines metastasis-competent cancer cells.\",\n      \"method\": \"ATAC-seq (chromatin accessibility), RNA-seq, cell migration/invasion assays, mouse metastasis models, ZBTB18 re-expression\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ATAC-seq genome-wide chromatin accessibility combined with in vivo metastasis models and specific pathway (TGFβ) validation using multiple orthogonal methods\",\n      \"pmids\": [\"36608120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZBTB18/RP58 haploinsufficiency in heterozygous knockout mice causes glutamatergic synaptic dysfunction, including reduced glutamate receptor expression, altered NMDA receptor-mediated synaptic responses, decreased LTP saturation, and altered thick-spine morphology, alongside corpus callosum dysplasia and behavioral/cognitive deficits.\",\n      \"method\": \"Heterozygous knockout mouse, electrophysiology (LTP, NMDA currents), Western blotting, spine morphology analysis, behavioral testing\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined cellular and synaptic phenotypes with multiple electrophysiological and molecular readouts in a loss-of-function mouse model, single lab\",\n      \"pmids\": [\"36721027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Hepatic ZBTB18 transcriptionally activates FXR (Farnesoid X receptor) to promote fatty acid oxidation and transcriptionally activates Clathrin Heavy Chain (CLTC) to inhibit NLRP3 inflammasome activity; hepatic ZBTB18 knockout promotes NAFLD features and insulin resistance, while overexpression alleviates hepatosteatosis.\",\n      \"method\": \"Hepatic-specific knockout and overexpression in mice, primary hepatocyte cultures, FXR deletion and forced expression, CLTC deletion, in vitro and in vivo mechanistic assays\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic epistasis via FXR and CLTC deletion to verify downstream mechanism, multiple in vivo and in vitro models with specific readouts\",\n      \"pmids\": [\"38263084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZBTB18 physically interacts with p21 to co-repress expression of cKit in hematopoietic stem cells (HSCs), regulating HSC self-renewal; Zbtb18 knockdown significantly impairs HSC reconstitution capability.\",\n      \"method\": \"Co-immunoprecipitation, p21-tdTomato reporter mouse, shRNA knockdown, HSC transplantation/reconstitution assay\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction by Co-IP, functional HSC reconstitution assay with knockdown, single lab\",\n      \"pmids\": [\"38721703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZBTB18 haploinsufficiency in mice leads to defective DNA repair, DNA and mitochondrial damage accumulation, and activated microglia in the dentate gyrus, contributing to early cognitive decline; these phenotypes are attenuated by minocycline treatment.\",\n      \"method\": \"Zbtb18 heterozygous knockout mice, DNA damage markers, mitochondrial morphology analysis, microglial activation assay, transcriptome analysis, behavioral testing, minocycline intervention\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function mouse with specific molecular (DNA repair, mitochondrial) and cellular (microglial) readouts, single lab with multiple methods\",\n      \"pmids\": [\"39396010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZBTB18 regulates cytokine production in glioblastoma cells, impairing secretion of chemoattractants for glioma-associated macrophages/microglia (GAMs); ZBTB18 expression in GBM cells reduces GAM migration and alters microglia commitment from immunosuppressive to pro-inflammatory phenotype in vivo.\",\n      \"method\": \"ZBTB18 re-expression in GBM cells, conditioned medium assays, in vivo tumor models, RNA-seq of conditioned microglia\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ZBTB18 expression-based functional experiments with in vivo validation and RNA-seq mechanistic readout, single lab\",\n      \"pmids\": [\"39516530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"T cell-derived IL-9 induces ZBTB18 expression in germinal center (GC) memory precursor B cells; ZBTB18 is required for GC-derived memory B cell development and directly represses cyclin and CDK genes, pro-apoptotic genes Bid and Casp3, and the GC-retaining receptor S1pr2, enabling memory B cell exit and survival.\",\n      \"method\": \"Adoptive transfer, radiation chimera models, conditional ZBTB18 knockout in B cells, ChIP, gene expression analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genetic epistasis (conditional KO), direct target identification by ChIP, multiple in vivo models across different cell types, mechanistic pathway (IL-9→ZBTB18→target genes) validated orthogonally\",\n      \"pmids\": [\"40107273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZBTB18 binds mammalian-specific cis-regulatory elements (CREs) associated with intratelencephalic (IT) and extratelencephalic (ET) neuron identity genes; deletion of Zbtb18 in mouse excitatory neurons dysregulates target gene expression, reduces neuronal molecular diversity, diminishes corticospinal and callosal projections, and increases intrahemispheric association projections, resembling non-mammalian dorsal pallium organization.\",\n      \"method\": \"ATAC-seq, RNA-seq, ChIP/CUT&RUN for ZBTB18 binding, conditional Zbtb18 knockout in excitatory neurons, axonal projection tracing, cross-species CRE conservation analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with direct genomic binding data and specific axonal projection phenotypes, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.05.20.652233\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZBTB18 forms a transcriptional repressive complex with FOXG1 involved in neuronal differentiation; missense variants within the BTB domain (in addition to the zinc finger domain) can be pathogenic, expanding the known domain regions where mutations disrupt ZBTB18 function.\",\n      \"method\": \"Whole-exome sequencing, clinical genetic analysis; BTB domain variant identified in monozygotic twins\",\n      \"journal\": \"Cytogenetic and genome research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — complex formation with FOXG1 stated but mechanistic experiment not described in abstract; BTB domain pathogenicity from clinical variant only\",\n      \"pmids\": [\"38056433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ZBTB18 inhibits muscle stem cell (MuSC) proliferation and promotes myogenic differentiation with a bias toward oxidative myofiber formation by acting as a transcriptional repressor of STAT1.\",\n      \"method\": \"ATAC-seq, RNA-seq in bovine MuSCs, functional proliferation/differentiation assays, ZBTB18 overexpression/knockdown, ChIP or reporter assay for STAT1 repression\",\n      \"journal\": \"Food chemistry. Molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — integrated ATAC-seq/RNA-seq plus functional myogenesis assays establishing STAT1 as direct transcriptional target, single lab\",\n      \"pmids\": [\"42256346\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZBTB18 is a BTB-POZ domain and multi-C2H2 zinc finger transcriptional repressor that directly binds DNA through its zinc finger domain to repress target genes (including proneurogenic genes Ngn2/NeuroD1/Pax6, PI3K subunits, SREBP genes, cKit, S1pr2, cyclin/CDK genes, and STAT1); it interacts with co-repressor/co-activator complexes including CTBP1/2 and LSD1, is post-translationally cleaved by calpain in glioblastoma generating a cytoplasmic N-terminal fragment that activates HIF1A targets, and is regulated epigenetically by promoter methylation; functionally, it is required for neuronal differentiation, corpus callosum development, excitatory synapse maturation, memory B cell development downstream of IL-9, suppression of tumor metastasis via chromatin compaction, fatty acid oxidation via FXR activation in hepatocytes, and hematopoietic stem cell self-renewal in complex with p21.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZBTB18 (RP58/ZNF238) is a BTB-POZ/C2H2 zinc-finger transcriptional repressor that controls cell-fate decisions across neural, immune, hematopoietic, hepatic, and muscle lineages by binding DNA through its zinc-finger domain to silence lineage- and proliferation-controlling gene programs [#0, #2, #4]. In the developing brain it directly represses the proneurogenic genes Ngn2 and NeuroD1 (and regulates Pax6), and its loss causes microencephaly, corpus callosum agenesis, cerebellar hypoplasia, and a shift from neuronal toward glial differentiation [#2]; it acts as an antiproliferative, pro-differentiation factor that lowers cyclin D1 and raises p27 and neuronal markers [#1]. Disease-associated missense variants clustered at DNA-contact residues of the zinc fingers alter DNA-binding specificity and transcriptional activity and impair neuronal radial migration, mechanistically tying specific residues to ZBTB18 function [#4, #5]. Repression is achieved through chromatin-modifying partners: ZBTB18 binds CTBP1/2 and LSD1 to scaffold repressive complexes and reduce LSD1 demethylase activity at target promoters, and genome-wide it reduces chromatin accessibility, compacting promoters of metastasis-driving genes such as Tgfbr2 to block TGFβ pathway activation and invasion [#8, #10]. Across other tissues ZBTB18 directly represses class I PI3K regulatory subunits to dampen PI3K signaling and restrain plasma cell differentiation [#7], co-represses cKit with p21 to govern hematopoietic stem cell self-renewal [#13], and is induced by IL-9 to drive memory B cell development by repressing cyclin/CDK, pro-apoptotic (Bid, Casp3), and the retention receptor S1pr2 genes [#16]. In glioblastoma ZBTB18 is silenced by promoter methylation and functions as a tumor suppressor whose re-expression reverses the aggressive phenotype [#3]; calpain cleavage generates a cytoplasmic N-terminal fragment that loses repressor activity and instead, via CTBP1/2, activates HIF1A target genes to promote lipid uptake and metabolic reprogramming [#9]. In hepatocytes ZBTB18 transcriptionally activates FXR and CLTC to promote fatty acid oxidation and limit NLRP3 inflammasome activity, protecting against NAFLD [#12].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing ZBTB18 as a neuron-enriched protein with a defined BTB/zinc-finger architecture set the structural basis for its candidacy as a sequence-specific transcriptional regulator.\",\n      \"evidence\": \"cDNA cloning, sequence analysis, and Northern/in situ expression mapping in brain\",\n      \"pmids\": [\"9568537\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No DNA target or transcriptional activity demonstrated\", \"Functional role inferred only from expression pattern\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Loss- and gain-of-function in neural cells answered whether ZBTB18 controls proliferation versus differentiation, defining it as an antiproliferative, pro-differentiation factor.\",\n      \"evidence\": \"shRNA knockdown in primary granule neuron precursors and overexpression in medulloblastoma/glioblastoma lines with marker readouts and xenograft assay\",\n      \"pmids\": [\"20103640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets not identified\", \"Mechanism of cyclin D1/p27 regulation not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"ChIP plus conditional knockout identified Ngn2 and NeuroD1 as direct repression targets and established ZBTB18 as required for neuronal differentiation and brain expansion.\",\n      \"evidence\": \"CNS-specific conditional knockout mouse, ChIP target validation, reporter assays, immunohistochemistry\",\n      \"pmids\": [\"22095278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor machinery at these promoters not defined\", \"Whether Pax6 is a direct vs indirect target unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapping disease variants to zinc-finger DNA-contact residues mechanistically connected specific amino acids to DNA binding, transcriptional output, and in vivo neuronal migration.\",\n      \"evidence\": \"Structural modeling, EMSA/DNA binding, luciferase reporters, in utero electroporation migration assays\",\n      \"pmids\": [\"31112317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide target consequences of variants not assessed\", \"Effect on co-repressor recruitment not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extending variant analysis to population variants clarified that DNA-contact residue mutations preferentially impair function while non-contact variants are often tolerated, refining genotype-function rules.\",\n      \"evidence\": \"EMSA/DNA binding and reporter transcriptional assays on multiple variants with structural analysis\",\n      \"pmids\": [\"32598555\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo phenotypic correlation for population variants lacking\", \"Single-lab in vitro assays only\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying CtBP2 as a physical partner in glioblastoma began defining the co-repressor complexes through which ZBTB18 acts.\",\n      \"evidence\": \"Co-immunoprecipitation, colocalization, shRNA knockdown, xenograft model in U-87 MG cells\",\n      \"pmids\": [\"32971103\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs bridged interaction not distinguished\", \"Target genes of the ZBTB18-CtBP2 complex not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"ChIP-seq in B cells answered how ZBTB18 restrains differentiation, showing it directly represses class I PI3K regulatory subunits to dampen PI3K signaling and block plasma cell differentiation.\",\n      \"evidence\": \"ChIP-seq, reporter assays, loss-of-function mouse and human B cell differentiation assays, mutant analysis\",\n      \"pmids\": [\"33608456\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor requirement at PI3K loci not defined\", \"Upstream signals controlling ZBTB18 levels in B cells unaddressed\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining ZBTB18-CTBP1/2-LSD1 complexes at SREBP promoters established a chromatin-modifying mechanism linking ZBTB18 to lipid metabolism in glioblastoma.\",\n      \"evidence\": \"Co-IP, ChIP with histone mark analysis, glucose tracing/mass spectrometry, metabolic assays\",\n      \"pmids\": [\"36414381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs scaffolding contribution of ZBTB18 to LSD1 activity not fully separated\", \"Generality beyond SREBP loci unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Discovery of calpain cleavage explained how a repressor can be converted to a metabolic activator, generating a cytoplasmic N-terminal fragment that engages CTBP1/2 and activates HIF1A targets.\",\n      \"evidence\": \"Mass spectrometry, subcellular fractionation, Co-IP, calpain inhibition, lipid assays\",\n      \"pmids\": [\"35800763\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cleavage site and regulation of calpain activation not fully mapped\", \"Mechanism of cytoplasmic HIF1A target activation unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Genome-wide chromatin accessibility profiling showed ZBTB18 enforces widespread chromatin closing, repressing Tgfbr2 and blocking TGFβ-driven metastasis, defining loss of ZBTB18 as a metastasis-enabling event.\",\n      \"evidence\": \"ATAC-seq, RNA-seq, migration/invasion assays, mouse metastasis models, re-expression\",\n      \"pmids\": [\"36608120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ZBTB18 directs broad chromatin compaction mechanistically not resolved\", \"Partner requirements for accessibility changes not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Haploinsufficient mice revealed a postnatal role in glutamatergic synapse maturation and cognition beyond developmental patterning.\",\n      \"evidence\": \"Heterozygous knockout mice, LTP and NMDA electrophysiology, Western blot, spine morphology, behavior\",\n      \"pmids\": [\"36721027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct synaptic gene targets not identified\", \"Cell-autonomy of synaptic deficits not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Clinical genetics extended pathogenic variation into the BTB domain and reported a FOXG1-containing repressive complex, broadening the functional domains and partner set.\",\n      \"evidence\": \"Whole-exome sequencing and clinical analysis in monozygotic twins\",\n      \"pmids\": [\"38056433\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"FOXG1 complex formation asserted but not mechanistically demonstrated\", \"BTB-domain variant pathogenicity from clinical association only\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Hepatic genetic models defined a metabolic-protective program in which ZBTB18 activates FXR and CLTC to drive fatty acid oxidation and limit NLRP3 inflammasome activity.\",\n      \"evidence\": \"Hepatic-specific knockout/overexpression mice, primary hepatocytes, FXR and CLTC deletion epistasis\",\n      \"pmids\": [\"38263084\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FXR/CLTC are direct ZBTB18 targets via repression or activation mechanistically reconciled with its repressor role unclear\", \"Tissue-specificity of activating function not explained\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying a ZBTB18-p21 complex repressing cKit established its role in hematopoietic stem cell self-renewal.\",\n      \"evidence\": \"Co-IP, p21-tdTomato reporter mouse, shRNA knockdown, HSC transplantation/reconstitution\",\n      \"pmids\": [\"38721703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cKit promoter binding by ZBTB18 not shown\", \"Single-lab interaction data\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Haploinsufficient mice linked ZBTB18 loss to defective DNA repair, mitochondrial damage, and microglial activation driving cognitive decline, reversible by minocycline.\",\n      \"evidence\": \"Heterozygous knockout mice, DNA damage and mitochondrial markers, microglial assays, transcriptome, behavior, drug intervention\",\n      \"pmids\": [\"39396010\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional control of DNA-repair genes not demonstrated\", \"Whether microglial phenotype is cell-autonomous vs secondary unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"ZBTB18 re-expression in glioblastoma was shown to reshape the tumor microenvironment by reducing chemoattractant secretion and shifting microglia toward a pro-inflammatory state.\",\n      \"evidence\": \"Re-expression in GBM cells, conditioned medium assays, in vivo tumor models, RNA-seq of conditioned microglia\",\n      \"pmids\": [\"39516530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct cytokine gene targets of ZBTB18 not defined\", \"Mechanism linking transcriptional repression to secretome change unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"IL-9 induction of ZBTB18 and ChIP target mapping established a cytokine-driven program enabling germinal center memory B cell exit and survival via repression of cyclin/CDK, pro-apoptotic, and S1pr2 genes.\",\n      \"evidence\": \"Adoptive transfer, radiation chimeras, conditional B cell knockout, ChIP, expression analysis\",\n      \"pmids\": [\"40107273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How IL-9 signaling induces ZBTB18 transcription not detailed\", \"Co-repressor machinery at these B cell loci not characterized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Integrating ZBTB18 binding at mammalian-specific cis-regulatory elements with conditional knockout connected ZBTB18 to evolutionarily novel cortical neuron diversity and projection identity.\",\n      \"evidence\": \"ATAC-seq, RNA-seq, ChIP/CUT&RUN, conditional knockout in excitatory neurons, axonal tracing, cross-species CRE analysis (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.05.20.652233\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Direct vs indirect control of IT/ET identity genes not fully separated\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"ATAC-seq/RNA-seq plus functional myogenesis assays extended ZBTB18's repressor role to muscle stem cells, showing repression of STAT1 promotes oxidative myofiber differentiation.\",\n      \"evidence\": \"ATAC-seq, RNA-seq in bovine MuSCs, proliferation/differentiation assays, ZBTB18 perturbation, STAT1 repression validation\",\n      \"pmids\": [\"42256346\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conservation of STAT1 repression in human/mouse muscle untested\", \"Co-repressor dependence at STAT1 locus not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ZBTB18 selects its tissue-specific target repertoire and switches between repressive (full-length, chromatin-compacting) and activating (cleaved/cytoplasmic; hepatic FXR/CLTC) outputs remains the central unresolved mechanistic question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model reconciling repressor activity with reported transcriptional activation of FXR/CLTC\", \"Structural basis for partner choice (CTBP1/2, LSD1, FOXG1, p21) across tissues unknown\", \"Determinants of context-specific cis-element binding not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 7, 8, 10, 16, 19]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 8]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 7, 8, 16, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 11, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 10]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 9, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CTBP1\", \"CTBP2\", \"LSD1\", \"ZNF217\", \"FOXG1\", \"CDKN1A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}